[VIRTUAL] Glofitamab Step-Up Dosing (SUD): Updated Efficacy Data Show High Complete Response Rates in Heavily Pretreated Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (Pts)

[VIRTUAL] OPTIC Primary Analysis: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (PON)

[VIRTUAL] The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma

[VIRTUAL] Long-Term Follow-up, Up to 7 Years, in the RESONATE-2 Study of FirstLine Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL)

[VIRTUAL] Pirtobrutinib (LOXO-305), a NextGeneration, Highly Selective, NonCovalent Bruton’s Tyrosine Kinase Inhibitor in Previously Treated Mantle Cell Lymphoma and Other Non-Hodgkin Lymphomas: Phase 1/2 BRUIN Study Results

[VIRTUAL] Primary Analysis of the Phase 2 ELARA Trial: Tisagenlecleucel Efficacy and Safety in Adult Patients with Relapsed/Refractory Follicular Lymphoma (r/r FL)

[VIRTUAL] First Results of a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia

[VIRTUAL] The BET Inhibitor Pelabresib Decreases Infl ammatory Cytokines, Improves Bone Marrow Fibrosis and Function, and Demonstrates Clinical Response Irrespective of Mutation Status in Myelofibrosis Patients in the Phase 2 MANIFEST Trial

[VIRTUAL] CheckMate 436: Extended Follow-Up from the Phase 2 Study Investigating Nivolumab Plus Brentuximab Vedotin (BV) for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (R/R PMBL)

[VIRTUAL] Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Updated Analyses of a Phase 1b Study

[VIRTUAL] The First-in-Class Anti-CD47 Antibody Magrolimab in Combination with Azacitidine Is Well Tolerated and Effective in AML Patients: Phase 1b Results

[VIRTUAL] Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study

[VIRTUAL] Five-Year Overall Survival from the CheckMate 205 Study of Nivolumab for Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL)

[VIRTUAL] Overall Survival with Tafasitamab + Lenalidomide (LEN) vs Routinely Administered Therapies for ASCT-Ineligible Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Outcomes from the Observational RE-MIND2 Study

[VIRTUAL] Melfl ufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed or Refractory to Prior Alkylators: A Pooled Analysis of the O-12-M1 and HORIZON Studies